Get started

BSX

🏥💼 Boston Scientific (BSX) Investment Analysis 💡📈Strategic Acquisitions: Boston Scientific's recent acquisitions, including Axonics, Relievant Medsystems, and partial offer for Acotec, signify its proactive expansion strategy, targeting new growth opportunities in medical segments and lucrative markets like China. Innovative Product Introductions: Introduction of innovative products strengthens Boston Scientific's industry position and demonstrates commitment to addressing unmet medical needs. Investment Outlook: Bullish sentiment on NYSE:BSX , fueled by strategic initiatives and potential for revenue growth. Upside target of $86.00-$88.00 reflects optimistic expectations for Boston Scientific's execution of growth strategies and capitalization on recent acquisitions and product launches. 📊🚀 Stay tuned for BSX's growth trajectory! #BostonScientific #InvestmentAnalysis 📈💼
NYSE:BSXLong
by Richtv_official
$BSX Soars to Record Highs: A Compelling Investment Opportunity With a recent surge to record highs, fueled by positive developments and robust financial performance, here's a compelling case for potential buyers to consider adding NYSE:BSX stock to their portfolios. 1. Technical Analysis: Riding the Rising Trend Channel Boston Scientific is currently riding a rising trend channel in the medium to long term, reflecting increasing optimism among investors. The stock has recently broken a rectangle formation, further indicating a strong bullish sentiment. The absence of resistance in the price chart suggests the potential for continued upward momentum. A decisive break of the resistance at $56.91 is anticipated to trigger a further rise to $58.50 or more. 2. Strategic Gap-Up and Buy Zone Expansion The recent gap-up in Boston Scientific's stock price on heavy volume, coupled with bypassing a key alternative buy point at $56.90, underscores strong positive momentum. Investors should take note that shares are currently within a 5% buy zone, extending up to $59.75. This presents an attractive entry point for those looking to capitalize on the stock's upward trajectory. 3. FARAPULSE Treatment Anticipation Boosts Confidence Boston Scientific's recent announcement regarding the anticipated FDA approval of its FARAPULSE treatment for a heart condition in the first quarter of 2024 has significantly boosted investor confidence. This development not only signals the company's commitment to innovation but also opens up new revenue streams, potentially driving the stock price higher. 4. Impressive Year-to-Date Performance With a remarkable 24% gain in the current year, Boston Scientific has consistently outperformed market expectations. The stock touched a record high on a recent Friday, showcasing the market's positive response to the company's strategic initiatives and strong financial performance. 6. Upgraded 2023 Earnings Outlook Notably, Boston Scientific raised its full-year 2023 earnings outlook in its latest report, reflecting management's confidence in sustained growth. Such positive guidance provides investors with a clear signal of the company's strong fundamentals and future potential. As Boston Scientific continues its upward trajectory, propelled by a confluence of positive technical indicators, strategic developments, and robust financial performance, now may be an opportune moment for investors to consider adding NYSE:BSX stock to their portfolios. The anticipation of FDA approval for FARAPULSE, coupled with the company's impressive year-to-date gains, positions Boston Scientific as a compelling investment opportunity with the potential for continued growth in the foreseeable future. As always, investors are encouraged to conduct thorough research and consult with financial advisors before making any investment decisions.
NYSE:BSX
by DEXWireNews
BSX. Long. Live. Snake.Can this be called testing after the breakdown of descending channel? Probably. Long candle wicks can indicate about low asset liquidity, therefore slightly spoiling the overall picture. Based on the fact that we probably tested descending channel and showed the 6th largest green bar of the histogram, it can be argued that this is a good entry point, considering that RSI stand in oversold zone for some time. In the short term, there will be bullish news for BSX and its ecosystem. This is a public fact, not insider information. BSX, personally, is my choice for investment and I consider it extremely undervalued and promising. DYOR
KRAKEN:BSXUSD
by Tropnik
1
MERCK IS DIRT CHEAP. $11 BILLION CANCER DRUG. SALES BOOMING!We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street Corruption at it's best! We took a long position at $82.00 several weeks ago. We feel the stock is worth at minimum, $150.00 all day long. KEYTRUDA alone, not counting any other products manufactured / developed by Merck, or any other divisions of Merck, is forecast to bring in over $11 Billion in sales. Holding for the almost 3% Dividend and for the stock price appreciation into the future. 250,000 LONG @ $82.00 Best of Luck Everyone!
NYSE:MRKLong
by UnknownUnicorn3159981
BSX - Upward channel breakdown short from $27.60 to $24.67 BSX hit its speculative entry as it broken below $29 label, and now it seems breaking down its Upward channel formation. We would consider a secondary entry at the confirmation break of upward channel around $27.60 * Trade Criteria * Date First Found- October 25, 2017 Pattern/Why- Upward channel breakdown short Entry Target Criteria- Break of $29 (Speculative entry); Confirmed Entry $27.60 Exit Target Criteria- $24.67 & Lower Stop Loss Criteria- N/A Please check back for Trade updates. (Note: Trade update is little delayed here.)
NYSE:BSXShort
by AcornWealthCorp